Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020;12(1):8.
Article
Google Scholar
Lianidou E, Pantel K. Liquid biopsies. Genes Chromosom Cancer. 2019;58(4):219–32. https://doi.org/10.1002/gcc.22695.
Article
CAS
PubMed
Google Scholar
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–91.
Article
CAS
Google Scholar
Bidard F-C, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, de Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014;15(4):406–14. https://doi.org/10.1016/S1470-2045(14)70069-5.
Article
PubMed
Google Scholar
Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, Pierga J-Y, Bidard FC. Circulating tumor cells: clinical validity and utility. Int J Clin Oncol. 2017;22(3):421–30. https://doi.org/10.1007/s10147-017-1105-2.
Article
PubMed
Google Scholar
Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene. 2016;35(10):1216–24.
Article
CAS
Google Scholar
Castro-Giner F, Aceto N. Tracking cancer progression: from circulating tumor cells to metastasis. Genome Med. 2020;12(1):31.
Article
Google Scholar
Keller L, Pantel K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer. 2019;19(10):553–67. https://doi.org/10.1038/s41568-019-0180-2.
Article
CAS
PubMed
Google Scholar
Aceto N, Bardia A, Wittner BS, Donaldson MC, O’Keefe R, Engstrom A, et al. AR expression in breast cancer CTCs associates with bone metastases. Mol Cancer Res MCR. 2018;16(4):720–7. https://doi.org/10.1158/1541-7786.MCR-17-0480.
Article
CAS
PubMed
Google Scholar
Kwan TT, Bardia A, Spring LM, Giobbie-Hurder A, Kalinich M, Dubash T, Sundaresan T, Hong X, LiCausi JA, Ho U, Silva EJ, Wittner BS, Sequist LV, Kapur R, Miyamoto DT, Toner M, Haber DA, Maheswaran S. A digital RNA signature of circulating tumor cells predicting early therapeutic response in localized and metastatic breast cancer. Cancer Discov. 2018;8(10):1286–99. https://doi.org/10.1158/2159-8290.CD-18-0432.
Article
CAS
PubMed
PubMed Central
Google Scholar
Miyamoto DT, Lee RJ, Kalinich M, LiCausi JA, Zheng Y, Chen T, et al. An RNA-based digital circulating tumor cell signature is predictive of drug response and early dissemination in prostate cancer. Cancer Discov. 2018;8(3):288–303. https://doi.org/10.1158/2159-8290.CD-16-1406.
Article
CAS
PubMed
PubMed Central
Google Scholar
Guarducci C, Bonechi M, Boccalini G, Benelli M, Risi E, Di Leo A, et al. Mechanisms of resistance to CDK4/6 inhibitors in breast cancer and potential biomarkers of response. Breast Care Basel Switz. 2017;12(5):304–8. https://doi.org/10.1159/000484167.
Article
Google Scholar
Condorelli R, Spring L, O’Shaughnessy J, Lacroix L, Bailleux C, Scott V, et al. Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(3):640–5.
Article
CAS
Google Scholar
Migliaccio I, Bonechi M, McCartney A, Guarducci C, Benelli M, Biganzoli L, et al. CDK4/6 inhibitors: a focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. Cancer Treat Rev. 2020;93:102136.
Article
Google Scholar
Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D’Hollander K, et al. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(8):1748–54.
Article
CAS
Google Scholar
Guarducci C, Bonechi M, Benelli M, Biagioni C, Boccalini G, Romagnoli D, Verardo R, Schiff R, Osborne CK, de Angelis C, di Leo A, Malorni L, Migliaccio I. Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer. 2018;4(1):38. https://doi.org/10.1038/s41523-018-0092-4.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ma Y, Luk A, Young FP, Lynch D, Chua W, Balakrishnar B, et al. Droplet digital PCR based androgen receptor variant 7 (AR-V7) detection from prostate cancer patient blood biopsies. Int J Mol Sci. 2016;17(8).
Dehm SM, Montgomery B, Plymate SR. AR-variant-positive CTC: a surrogate for a surrogate for taxane therapy outcome? Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(6):1696–8.
Article
Google Scholar
Huang X, Gao P, Song Y, Sun J, Chen X, Zhao J, et al. Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch system in colorectal cancer. BMC Cancer. 2015;15 Disponibile su: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389311/. [citato 19 aprile 2020].
Yang C, Zou K, Yuan Z, Guo T, Xiong B. Prognostic value of circulating tumor cells detected with the CellSearch system in patients with gastric cancer: evidence from a meta-analysis. OncoTargets Ther. 2018;11:1013–23. https://doi.org/10.2147/OTT.S154114.
Article
Google Scholar
Pierga J-Y, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Diéras V, Rolland E, Mignot L, Mathiot C, Bidard FC. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol Off J Eur Soc Med Oncol. 2012;23(3):618–24. https://doi.org/10.1093/annonc/mdr263.
Article
Google Scholar
Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(7):1420–30.
Article
Google Scholar
Shiomi-Mouri Y, Kousaka J, Ando T, Tetsuka R, Nakano S, Yoshida M, Fujii K, Akizuki M, Imai T, Fukutomi T, Kobayashi K. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer. Breast Cancer Tokyo Jpn. 2016;23(1):120–7. https://doi.org/10.1007/s12282-014-0539-x.
Article
Google Scholar
Bonechi M, Galardi F, Biagioni C, De Luca F, Bergqvist M, Neumüller M, et al. Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. Oncotarget. 2018;9(23):16389–99.
Article
Google Scholar
Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(31):5153–9.
Article
Google Scholar
Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, Tsunoda N, Ito Y, Tokudome N, Toi M, Kuroi K, Suzuki E. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer Tokyo Jpn. 2010;17(3):199–204. https://doi.org/10.1007/s12282-009-0139-3.
Article
Google Scholar
Hartkopf AD, Wagner P, Wallwiener D, Fehm T, Rothmund R. Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. Anticancer Res. 2011;31(3):979–84.
PubMed
Google Scholar
Deutsch TM, Stefanovic S, Feisst M, Fischer C, Riedel F, Fremd C, et al. Cut-off analysis of CTC change under systemic therapy for defining early therapy response in metastatic breast cancer. Cancers. 2020;12(4).
Rossi L, Biagioni C, McCartney A, Migliaccio I, Curigliano G, Sanna G, et al. Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial. Breast Cancer Res BCR. 2019;21(1):71.
Article
Google Scholar
Schochter F, Friedl TWP, de Gregorio A, Krause S, Huober J, Rack B, et al. Are circulating tumor cells (CTCs) ready for clinical use in breast cancer? An overview of completed and ongoing trials using CTCs for clinical treatment decisions. Cells. 2019;8(11).
Bidard F-C, Jacot W, Kiavue N, Dureau S, Kadi A, Brain E, et al. Efficacy of circulating tumor cell count-driven vs clinician-driven first-line therapy choice in hormone receptor-positive, ERBB2-negative metastatic breast cancer: the STIC CTC randomized clinical trial. JAMA Oncol. 2021;7(1):34–41.
Article
Google Scholar
Tagawa ST, Antonarakis ES, Gjyrezi A, Galletti G, Kim S, Worroll D, et al. Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(6):1880–8.
Article
CAS
Google Scholar
McCartney A, Migliaccio I, Bonechi M, Biagioni C, Romagnoli D, De Luca F, et al. Mechanisms of resistance to CDK4/6 inhibitors: potential implications and biomarkers for clinical practice. Front Oncol. 2019;9:666. https://doi.org/10.3389/fonc.2019.00666.
Article
PubMed
PubMed Central
Google Scholar
Pandey K, An H-J, Kim SK, Lee SA, Kim S, Lim SM, et al. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: a review. Int J Cancer. 2019;145(5):1179–88.
Article
CAS
Google Scholar
Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 2016;76(8):2301–13.
Article
CAS
Google Scholar
Peeters DJE, De Laere B, Van den Eynden GG, Van Laere SJ, Rothé F, Ignatiadis M, et al. Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. Br J Cancer. 2013;108(6):1358–67.
Article
CAS
Google Scholar
Fabbri F, Carloni S, Zoli W, Ulivi P, Gallerani G, Fici P, et al. Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Lett. 2013;335(1):225–31.
Article
CAS
Google Scholar
Salvianti F, Rotunno G, Galardi F, De Luca F, Pestrin M, Vannucchi AM, et al. Feasibility of a workflow for the molecular characterization of single cells by next generation sequencing. Biomol Detect Quantif. 2015;5:23–9. https://doi.org/10.1016/j.bdq.2015.07.002.
Article
CAS
PubMed
PubMed Central
Google Scholar
De Luca F, Rotunno G, Salvianti F, Galardi F, Pestrin M, Gabellini S, et al. Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. Oncotarget. 2016;7(18):26107–19.
Article
Google Scholar
Molecular Cloning: A Laboratory Manual, 3rd ed., Vols 1,2 and 3 J.F. Sambrook and D.W. Russell, ed., Cold Spring Harbor Laboratory Press, 2001, 2100 pp., soft cover | Sigma-Aldrich [Internet]. 2020 [citato 19 aprile 2020]. Disponibile su: https://www.sigmaaldrich.com/catalog/product/sigma/m8265?lang=it®ion=IT
Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L, et al. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol Oncol. 2015;9(4):749–57. https://doi.org/10.1016/j.molonc.2014.12.001.
Article
CAS
PubMed
Google Scholar
Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(14):1169–78.
Article
CAS
Google Scholar
Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee K-M, Hutchinson KE, et al. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. Cancer Res. 2017;77(9):2488–99.
Article
CAS
Google Scholar
Costa C, Wang Y, Ly A, Hosono Y, Murchie E, Walmsley CS, Huynh T, Healy C, Peterson R, Yanase S, Jakubik CT, Henderson LE, Damon LJ, Timonina D, Sanidas I, Pinto CJ, Mino-Kenudson M, Stone JR, Dyson NJ, Ellisen LW, Bardia A, Ebi H, Benes CH, Engelman JA, Juric D. PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast cancer. Cancer Discov. 2020;10(1):72–85. https://doi.org/10.1158/2159-8290.CD-18-0830.
Article
CAS
PubMed
Google Scholar
Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the hippo pathway. Cancer Cell. 2018;34(6):893–905.e8.
Article
Google Scholar
Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, et al. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nat Commun. 2019;10(1):1373.
Article
Google Scholar
Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, Kim D, Luo F, Mao P, Helvie K, Kowalski KJ, Nayar U, Waks AG, Parsons SH, Martinez R, Litchfield LM, Ye XS, Yu C, Jansen VM, Stille JR, Smith PS, Oakley GJ, Chu QS, Batist G, Hughes ME, Kremer JD, Garraway LA, Winer EP, Tolaney SM, Lin NU, Buchanan SG, Wagle N. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov. 2020;10(8):1174–93. https://doi.org/10.1158/2159-8290.CD-19-1390.
Article
CAS
PubMed
Google Scholar